Wieland Capital

Cycuria Therapeutics is a biotechnology company focused on developing innovative protein-based therapies for treating blood cancers, with a particular emphasis on acute myeloid leukemia (AML). The company's approach involves creating engineered proteins that selectively target and eliminate leukemic stem cells and AML blasts, while preserving healthy blood cells. This targeted strategy aims to reduce treatment-related toxicity, stimulate the immune system, and improve overall patient outcomes for AML and other challenging cancer types.

Noscendo GmbH is a diagnostics company based in Duisburg, Germany, focused on the development of bioinformatics solutions for identifying and assessing pathogens associated with bloodstream infections. Utilizing Next Generation Sequencing technology, Noscendo's platform offers a hypothesis-free approach to detect a wide range of infection-causing microbes, including bacteria, fungi, DNA viruses, and parasites, from a single standard blood draw. This innovative method eliminates the need for prior cultivation or specific knowledge about the infection's nature, empowering intensive care clinicians to make accurate distinctions between commensals, contamination, and genuine infections. Through its proprietary algorithms, Noscendo enhances the identification process, ultimately aiming to improve patient outcomes in critical care settings.

Lifespin is a data-driven company focused on mapping human health conditions through advanced technology. The company has developed a scalable platform that digitizes metabolomes on a population level, enabling the transformation of blood samples into digital representations. By employing AI-enhanced Nuclear Magnetic Resonance, Lifespin generates metabolic insights that contribute to precision medicine. They have established a baseline for human health, allowing for the identification of individual deviations in patients. Lifespin's digital products cater to both healthcare providers and patients, facilitating early detection and monitoring of diseases while offering moderate-cost health testing for preventative care, diagnostics, and treatment.

Noscendo GmbH is a diagnostics company based in Duisburg, Germany, focused on the development of bioinformatics solutions for identifying and assessing pathogens associated with bloodstream infections. Utilizing Next Generation Sequencing technology, Noscendo's platform offers a hypothesis-free approach to detect a wide range of infection-causing microbes, including bacteria, fungi, DNA viruses, and parasites, from a single standard blood draw. This innovative method eliminates the need for prior cultivation or specific knowledge about the infection's nature, empowering intensive care clinicians to make accurate distinctions between commensals, contamination, and genuine infections. Through its proprietary algorithms, Noscendo enhances the identification process, ultimately aiming to improve patient outcomes in critical care settings.